4
Changes in Ownership
RHYTHM PHARMACEUTICALS, INC. Filed Acc 0001104659-24-117942
EVP, Head of North America sold 66,861 shares at an average $66.33 ($4,434,882)
- EVP, Head of North America acquired 60,981 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Option exercise 10b5-1 | +20,622 | $6.80 | $140,230 | 27,474 | D |
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Option exercise 10b5-1 | +28,717 | $24.29 | $697,536 | 56,191 | D |
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Option exercise 10b5-1 | +11,642 | $30.66 | $356,944 | 67,833 | D |
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Sale 10b5-1 | −38,051 | $65.68 | $2,499,049 | 29,782 | D |
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Sale 10b5-1 | −17,540 | $66.95 | $1,174,275 | 12,242 | D |
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Sale 10b5-1 | −11,070 | $67.56 | $747,873 | 1,172 | D |
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Sale 10b5-1 | −200 | $68.43 | $13,686 | 972 | D |
| Derivatives | |||||||
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,622 | 25,790 | D | ||
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −28,717 | 71,283 | D | ||
| Lee Jennifer Kayden EVP, Head of North America | 2024-11-11 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,642 | 37,108 | D | ||
| Open-market sales · 66,861 sh · avg $66.33 · $4,434,882 | |||||||
Loading xslF345X05/tm2428383-1_4seq1.xml…